Nektar TherapeuticsNKTRNASDAQ
LOADING
|||
Net Income Growth Under Pressure
Trending lower, above historical average.
Left:
||||
Year-over-year net income growth rate
Latest
14.60%
↑ 206% above average
Average (39q)
-13.74%
Historical baseline
Range
High:1114.13%
Low:-800.76%
CAGR
NaN%
Modest growth trend
| Period | Value |
|---|---|
| Q3 2025 | 14.60% |
| Q2 2025 | 18.26% |
| Q1 2025 | -800.76% |
| Q4 2024 | 119.59% |
| Q3 2024 | 29.23% |
| Q2 2024 | -42.28% |
| Q1 2024 | 12.54% |
| Q4 2023 | 8.20% |
| Q3 2023 | 10.34% |
| Q2 2023 | 62.69% |
| Q1 2023 | -129.56% |
| Q4 2022 | -1.08% |
| Q3 2022 | 62.88% |
| Q2 2022 | -75.97% |
| Q1 2022 | 37.94% |
| Q4 2021 | -12.29% |
| Q3 2021 | -3.34% |
| Q2 2021 | -2.08% |
| Q1 2021 | -4.92% |
| Q4 2020 | -7.94% |
| Q3 2020 | -35.73% |
| Q2 2020 | 42.30% |
| Q1 2020 | -23.61% |
| Q4 2019 | -13.52% |
| Q3 2019 | 10.10% |
| Q2 2019 | 7.26% |
| Q1 2019 | -20.67% |
| Q4 2018 | -2.15% |
| Q3 2018 | -109.90% |
| Q2 2018 | 1114.13% |
| Q1 2018 | -183.19% |
| Q4 2017 | -155.57% |
| Q3 2017 | 201.67% |
| Q2 2017 | 6.26% |
| Q1 2017 | -51.34% |
| Q4 2016 | 2.37% |
| Q3 2016 | 11.07% |
| Q2 2016 | -149.27% |
| Q1 2016 | 63.98% |
| Q4 2015 | -559.97% |